Appointment of Non-Executive Director and changes to Board committees

05 Aug 2020

REDX PHARMA PLC

(“Redx” or “the Company”)

 

Appointment of Non-Executive Director and changes to Board committees

 

Alderley Park, 5 August 2020 Redx Pharma (AIM:REDX), the drug discovery and development company focused on cancer and fibrosis, is pleased to announce, following the successful completion of the loan note fundraising and receipt of funds, the appointment of Thomas (“Tom”) Burt as a Non-Executive Director with effect from 4 August 2020. Tom brings extensive investment experience in the sector to his role at Redx and will represent Sofinnova on the Board of Directors under the terms of the Subscription for shares by Sofinnova Crossover 1 SLP (“Sofinnova”).

 

Tom has been a Partner in the Crossover fund at Sofinnova Partners since its inception in 2017. Prior to this, he was a Research Analyst covering UK healthcare and life science equities at Peel Hunt, joining in 2015 after six years as an Investment Director at specialist life science investors; Ares Life Sciences and Novo Holdings. Before this, he spent four years in the Healthcare Investment Banking team at Piper Jaffray & Co. Tom holds an Engineering Doctorate from UCL in Biochemical Engineering & Bioprocess Leadership, an MSc in Biochemical Engineering and a BSc in Biotechnology.

 

Iain Ross, Chairman of the Board of Redx commented: “We are delighted to welcome such an experienced director onto the Redx Board. I am looking forward to working with Tom and to ensuring that we grow Redx into a substantive biotech company.”    

 

Tom Burt commented: ” Redx is a company led by a highly talented management team with a proven track record for success, developing drugs in areas of high unmet medical need. I am pleased to be joining the board as a non-executive director and helping the Company drive forward its next phase of growth.” 

 

Board Committee Changes

Following the enlargement of the board, and with effect from 4 August 2020, Iain Ross will step down from his membership of the Remuneration and Audit & Governance committees. Sarah Gordon Wild will join these committees as an independent Non-Executive Director with effect from the same date.

 

 

Additional information:

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

 

Thomas Henry Burt, aged 40, is currently a director of:

 

  • Sofinnova Crossover 1 SLP

 

He does not currently hold any ordinary shares in the Company.

 

For further information, please contact:

 

Redx Pharma Plc  T: +44 1625 469 918
Iain Ross, Chairman

Lisa Anson, Chief Executive

 
SPARK Advisory Partners Limited (Nominated Advisor)  T: +44 20 3368 3550
Matt Davis/Henry Todd/Adam Dawes
WG Partners LLP (Broker) T: +44 20 3705 9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727 1000
Simon Conway/Ciara Martin

 

 

About Redx Pharma Plc

 

Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx’s vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/